Pherecydes Pharma Logo

Pherecydes Pharma

Develops precision phage therapy to treat resistant bacterial infections.

ALPHE | PA

Overview

Corporate Details

ISIN(s):
FR0011651694
LEI:
894500LYT3UUN58X3I68
Country:
France
Address:
22 BD BENONI GOULLIN, NANTES BIOTECH, 44200 NANTES
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Pherecydes Pharma is a biotechnology company that specializes in developing treatments for resistant bacterial infections. The company pioneers precision phage therapy, an approach that uses bacteriophage viruses (phages) to specifically target and combat harmful bacteria. This personalized therapeutic strategy is designed to treat severe and complicated infections that are unresponsive to conventional antibiotics. Founded in 2006, the company focuses on creating a portfolio of phages effective against critical bacterial pathogens. In June 2023, Pherecydes Pharma merged with Erytech Pharma to become Phaxiam Therapeutics, continuing its work in the fight against antimicrobial resistance.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-06-23 20:45
AGM Information
Informations privilégiées / Autres communiqués
French 214.3 KB
2023-06-23 20:45
AGM Information
Inside Information / Other news releases
English 213.8 KB
2023-06-14 20:00
Legal Proceedings Report
Inside Information / Other news releases
English 197.1 KB
2023-06-14 20:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 200.6 KB
2023-06-08 07:30
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 297.3 KB
2023-06-08 07:30
Regulatory Filings
Inside Information / Other news releases
English 269.4 KB
2023-06-05 08:00
Legal Proceedings Report
Inside Information / Other news releases
English 198.4 KB
2023-06-05 08:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 192.1 KB
2023-06-02 20:00
Pre-Annual General Meeting Information
Modalités de mise à disposition des documents préparatoires à l'AG
French 152.4 KB
2023-05-23 23:43
M&A Activity
News releases during takeover bids / Takeover bids Other news releases
English 191.8 KB
2023-05-23 23:43
Registration Form
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres comm…
French 184.9 KB
2023-05-16 07:00
M&A Activity
Inside Information / Other news releases
English 224.2 KB
2023-05-16 07:00
M&A Activity
Informations privilégiées / Autres communiqués
French 216.3 KB
2023-05-11 18:00
Capital/Financing Update
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
French 200.6 KB
2023-04-27 18:00
Report Publication Announcement
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
French 195.2 KB

Automate Your Workflow. Get a real-time feed of all Pherecydes Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pherecydes Pharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pherecydes Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Gubra A/S Logo
CRO & biotech accelerating peptide drug discovery for metabolic and fibrotic diseases.
Denmark
GUBRA
HALOZYME THERAPEUTICS, INC. Logo
Licenses a drug delivery platform to biopharma, converting IV drugs to subcutaneous injections.
United States of America
HALO
HEALIOS K.K. Logo
Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.
Japan
4593
HeartSciences Inc. Logo
AI-powered ECG technology for early detection of heart disease and advanced diagnostics.
United States of America
HSCS
Heartseed株式会社 Logo
Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.
Japan
219A
Herantis Pharma Oyj Logo
Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.
Finland
HRTIS
Hipower Energy Spolka Akcyjna Logo
Develops hydrogen solutions, mobile refueling, and CO2-to-methanol tech for energy markets.
Poland
HPE
HLB bioStep Co.,Ltd. Logo
South Korea
278650
HLB PANAGENE Co., LTD. Logo
A global leader in PNA technology for cancer diagnostics and precision medicine.
South Korea
046210
HLB SCIENCE Inc. Logo
Develops innovative therapeutics and diagnostics for infectious and neurodegenerative diseases.
South Korea
343090

Talk to a Data Expert

Have a question? We'll get back to you promptly.